Redx Pharma
Alderley Edge, United Kingdom

Redx Pharma specialises in the discovery and development of small molecule therapeutics, with an emphasis on oncology and fibrotic disease. It aims to initially progress them through proof-of-concept studies, before evaluating options for further development and value creation. Existing earlier-stage collaboration partners include AstraZeneca and Jazz Pharmaceuticals.

Investment Perspective

Redx Pharma is a UK-based clinical stage drug discovery company that specialises in developing highly targeted small molecules based on its proven medicinal chemistry expertise and research platform discovery engine. These are either “best-in-class” or “first-in-class” and target existing unmet needs in selected oncology and fibrosis indications. A driven management team is implementing a focussed and ambitious strategy which should transform the business over the medium term. This approach has been validated by a series of out-licensing and partnering deals. Knowledgeable and supportive shareholders have rebuilt the balance sheet, but further funding is required to capitalise on the existing opportunities. Our valuation, based on conservative assumptions, is £434m, equivalent to 157.5p/share.

Market information

SymbolPrimary exchanges


RXC008 nominated as GI-ROCK drug candidate
Lighthouse | 30 Mar 2022
Building on an impressive track-record
Outlook | 17 Feb 2022
FY21 results: a year of continuing delivery
Update | 27 Jan 2022

Recent News

RXC004 data to be presented at ASCO
27 Apr 2022
RXC004 preclinical data presented at AACR
08 Apr 2022
Collaboration with Garvan Institute of Medical Research
05 Apr 2022
RXC008 nominated as GI ROCK clinical development candidate
30 Mar 2022